Regression analysis | P value | P value | Propensity score analysis | P value | P value | |||
Unadjusted | Adjusted | Matching | IPTW | |||||
Risk ratio (95% CI) | Risk ratio (95% CI) | Risk ratio (95% CI) | Risk ratio (95% CI) | |||||
HD | (Reference) | (Reference) | (Reference) | (Reference) | ||||
Non-HD | 1.04 (0.92 to 1.19) | 0.50 | 1.09 (0.92 to 1.29) | 0.30 | 1.08 (0.81 to 1.45) | 0.60 | 1.09 (0.94 to 0.26) | 0.25 |
Age (year) | - | 1.03 (0.97 to 1.08) | 0.31 | - | - | |||
Male | - | 1.22 (1.08 to 1.38) | <0.001 | - | - | |||
Clinical day of IVIG | - | 0.83 (0.74 to 0.94) | 0.002 | - | - | |||
Serum Na (mEq/L) | - | 0.94 (0.91 to 0.98) | <0.001 | - | - | |||
AST (IU/L) | - | 1.00 (1.00 to 1.00) | <0.001 | - | - | |||
% of Neutrophil | - | 1.02 (1.01 to 1.03) | 0.001 | - | - | |||
Platelet count (109/L) | - | 1.00 (1.00 to 1.00) | <0.001 | - | - | |||
C reactive protein (mg/dL) | - | 1.02 (1.01 to 1.03) | <0.001 | - | - |
Additionally, online supplemental tables S2 an S3 summarise the results of the multivariable analysis for the risk of developing CALs and unresponsiveness to the initial IVIG treatment based on the use of low-dose ASA within the non-HD group.
ASA, acetylsalicylic acid; AST, aspartate aminotransferase; CALs, coronary artery lesions; HD, high dose; IPTW, inverse probability of treatment weighting; IVIG, intravenous immunoglobulin.